Cytokinetics to Present at HCMS Scientific Sessions and HFSA Annual Meeting

Cytokinetics, Incorporated has announced its participation in several key events focused on hypertrophic cardiomyopathy (HCM) and heart failure in late September 2024. The company will be presenting significant findings from its SEQUOIA-HCM trial on the effects of Aficamten on clinical outcomes, along with other related studies at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions and the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Atlanta, Georgia.

During the HCMS Scientific Sessions on September 27, three presentations will spotlight Aficamten and its impact. The first is an oral abstract titled "Global Remodeling Changes with Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Analysis of the SEQUOIA-HCM Trial," presented by Dr. Anjali T. Owens from the University of Pennsylvania. This session is scheduled for 11:00 AM to 12:00 PM ET at the Signia by Hilton in the Atlanta Georgia World Congress Center.

Following this, two poster abstract presentations will also take place on the same day. Dr. Juan R. Gimeno from Hospital Universitario Virgen de la Arrixaca, Spain, will present "Efficacy and Safety of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Very High Left Ventricular Outflow Tract Gradients" during the Closing Remarks & Poster Cocktail Reception from 4:00 PM to 5:00 PM ET. Concurrently, Dr. Morris M. Kim from Oregon Health & Science University will discuss "Beta-Blocker Use and Incidence of New Atrial Fibrillation or Flutter Requiring Therapy in Post-Septal Myectomy Hypertrophic Cardiomyopathy Patients."

At the HFSA Annual Scientific Meeting, Dr. Martin Maron from Lahey Hospital and Medical Center will deliver a presentation on September 30 titled "Global Clinical Impact of Aficamten in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM." This plenary session will run from 9:00 AM to 10:30 AM ET, with Dr. Maron's presentation scheduled for 9:20 AM to 9:28 AM ET, held in the Georgia World Congress Center’s Georgia Ballroom 2.

Cytokinetics is a biopharmaceutical company specializing in cardiovascular diseases by developing muscle biology-directed drug candidates. Aficamten, a cardiac myosin inhibitor, is one of their key developments aimed at treating obstructive hypertrophic cardiomyopathy. Positive results from their SEQUOIA-HCM trial have been published in the New England Journal of Medicine, setting the stage for regulatory submissions for Aficamten.

In addition to SEQUOIA-HCM, Aficamten is undergoing evaluation in the MAPLE-HCM trial as a monotherapy compared to metoprolol for obstructive HCM, the ACACIA-HCM trial for non-obstructive HCM, the CEDAR-HCM trial involving pediatric patients with obstructive HCM, and the FOREST-HCM open-label extension study.

Beyond Aficamten, Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator for heart failure patients, and CK-586, another cardiac myosin inhibitor with a unique mechanism for treating heart failure with preserved ejection fraction (HFpEF).

Cytokinetics continues to push forward with innovative treatments to address critical needs in cardiovascular medicine, as evidenced by their active participation and forthcoming presentations at these significant scientific gatherings.